Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › WINDLAS

WINDLAS

Windlas Biotech Limited
Micro-capPharma ↗

What the six lenses say about WINDLAS — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹1154.8
2026-09-08
VWAP · 1Y anchor
₹883
+30.7% from VWAP
P/E · TTM
36.6×
TTM EPS ₹31.6
52-week range
100%
position low→high
RSI(14)
81
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How WINDLAS’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
5.5
avg conviction decile
Leadership
—
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Micro-cap cohortDRaw
TechnicalD10100›

The actual numbers

Price vs VWAP (1y)+30.7%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+33.1%
Price vs 50-EMA+23.0%
RSI(14)81
RS vs Nifty 500 · 3M+37.4%
RS vs sector · 3M+31.4%
52-week range100%
Volume vs 30d avg0.47×
Volume vs 60d avg0.79×
ATR(14) · volatility54.3
Bollinger width · vol contraction0.276
FundamentalD752›

The actual numbers

Return on equity (ROE)11.5%
Operating margin10.1%
Net margin7.4%
Revenue growth · YoY+18.8%
EPS growth · YoY+8.2%
Debt / equity0.06×

Full 8-quarter history in the financials table below.

ValuationD421›

The actual numbers

P/E (TTM)36.6×
TTM EPS₹31.6
52-week range100%
CatalystD536›

The actual numbers

Earnings & momentum35
Capital actions14
Governance80

Every filing in the corporate-announcements panel below.

FlowD132›

The actual numbers

Promoter holding63.3%
Delivery · 30d avg46.8%
Up/down-day asymmetry-2.6pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Micro-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D10 + D1 ) ÷ 2 = 5.5(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
93
Conviction score 93/100 · avg-decile strength 5.5/10
Conviction score93/100›
TechnicalD10›
FundamentalD7›
ValuationD4›
CatalystD5›
FlowD1›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+3.0pp
+17.4pp
+35.6pp
+39.0pp
+58.1pp
+18.0pp
Nifty 500
Broad-market baseline
+2.9pp
+17.4pp
+34.6pp
+37.4pp
+52.3pp
+12.8pp
Sector
Own-sector index
—
—
+31.7pp
+31.4pp
+39.2pp
-8.0pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

WINDLAS daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
1154.75+28.40

Relative strength

RS vs baseline · rebased to 100

WINDLAS ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
130.41+3.74

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)175187195203210222233238
↳ change QoQ—+6.8%+4.3%+4.1%+3.4%+5.7%+5.0%+2.1%
EBITDA (₹cr)2528292627292425
EBITDA margin14.3%14.9%14.7%12.8%12.9%13.1%10.3%10.5%
PAT (₹cr)1316161618181516
↳ change QoQ—+16.2%-0.5%+2.7%+12.5%+0.0%-16.7%+6.7%
Net margin7.7%8.4%8.0%7.9%8.6%8.1%6.4%6.7%
EPS (₹)6.477.497.457.778.438.457.127.58
D/E————————
YoY growth · Mar '26Revenue +17.2% YoYPAT +0.0% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 1 Sep '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 14 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 11 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 10 Aug '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 10 Aug '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 10 Aug '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 5 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 5 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 9 Jul '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 2 Jul '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 1 Jul '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 29 Jun '26
    MEDIUMcapital
    Credit Rating
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 26 Jun '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 24 Jun '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 24 Jun '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds WINDLAS

Mutual funds holding WINDLAS (2)

FundWeightAUM ₹crGrade
ICICI Pru Pharma Healthcare Diag Gr0.75%6,803
UTI Healthcare Reg Gr1.17%1,371

ETFs holding WINDLAS (0)

No tracked ETF holds WINDLAS ≥0.5%.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma